01 1Vyndaqel Family
02 5Vyndaqel/Vyndamax
Main Therapeutic Indication : Rare Disorders
Currency : USD
2019 Revenue in Millions : 473
2018 Revenue in Millions : 148
Growth (%) : 220
Main Therapeutic Indication : Rare Disorders
Currency : USD
2020 Revenue in Millions : 1,288
2019 Revenue in Millions : 473
Growth (%) : 172
Main Therapeutic Indication : Rare Disorders
Currency : USD
2021 Revenue in Millions : 2,015
2020 Revenue in Millions : 1,288
Growth (%) : 56
Main Therapeutic Indication : Rare Diseases
Currency : USD
2022 Revenue in Millions : 2,447
2021 Revenue in Millions : 2,015
Growth (%) : 21
Main Therapeutic Indication : Rare Diseases
Currency : USD
2023 Revenue in Millions : 3,321
2022 Revenue in Millions : 2,447
Growth (%) : 36
Main Therapeutic Indication : Rare Diseases and Disorders
Currency : USD
2024 Revenue in Millions : 5,451
2023 Revenue in Millions : 3,321
Growth (%) : 64
